Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate

Schizophrenia Research

Volumn 53, Issue 1-2, 2002, Pages 25-30

  Marder, S R ^a,b   Aravagiri, M ^a   Wirshing, W C ^a   Wirshing, D A ^a   Lebell, M ^a   Mintz, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Fluphenazine; Schizophrenia

Indexed keywords

FLUPHENAZINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MONITORING; HUMAN; MENTAL DISEASE; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZATION; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FLUPHENAZINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0036132925     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(00)00184-5     Document Type: Article

References (16)

1. Negative symptoms in schizophrenia
2. A rating scale for drug induced akathisia
3. Low serum neuroleptic levels predict relapse in schizophrenic patients
4. Environmental/personal indicators in the course of schizophrenia research group. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: Results of a two-year controlled study
5. Low dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates
6. Fluphenazine plasma levels, dosage, efficacy, and side effects
7. Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with coulometric detection
8. The pharmacokinetics of long-acting injectable neuroleptic drugs: Clinical implications
9. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response
10. Low and conventional dose maintenance therapy with fluphenazine decanoate: Two year outcome
11. Monitoring plasma levels of fluphenzine during chronic therapy with fluphenazine decanoate
12. The brief psychiatric rating scale
13. Relapse and rehospitalization during maintenance treatment of schizophrenia
14. A rating scale for extrapyramidal side effects
15. A depot neuroleptic withdrawl study: Plasma concentration of fluphenazine and flupenthixol and relapse frequency